Usl Umbria 1, Perugia, Italy.
Usl Umbria 1, Perugia, Italy.
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
The first cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or COVID-19) infections were recorded in China in November 2019. Since its appearance in China at the end of last year, the virus has spread to all continents causing a "global pandemic". To date, some aspects remain to be investigate about the pathophysiology of this viral infection. One of the aspects to be still clarified is the correlation between the renin-angiotensin system (RAS) and SARS-CoV-2 infection. RAS is a physiological system playing a key role in different human body functions regulation. SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE-2), a component of RAS, as a potential factor of cell penetration and infectivity; in addition, in the different infection stages, a functional variation of the RAS has been noted. In this article, we discuss the correlation between the role of RAS and system-modifying agents, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs) and direct renin inhibitors (DRIs), with SARS-CoV-2 infection.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2 或 COVID-19)感染的首例病例于 2019 年 11 月在中国记录。自去年年底在中国出现以来,该病毒已传播到所有大陆,造成“全球大流行”。迄今为止,关于这种病毒感染的病理生理学仍有一些方面需要研究。其中一个需要澄清的方面是肾素-血管紧张素系统(RAS)与 SARS-CoV-2 感染之间的相关性。RAS 是一个在调节人体不同功能方面发挥关键作用的生理系统。SARS-CoV-2 使用血管紧张素转换酶 2(ACE-2),即 RAS 的一个组成部分,作为细胞穿透和传染性的潜在因素;此外,在不同的感染阶段,RAS 的功能发生了变化。在本文中,我们讨论了 RAS 及其系统修饰剂(血管紧张素转换酶抑制剂[ACEI]、血管紧张素 II 受体阻滞剂[ARB]和直接肾素抑制剂[DRI])与 SARS-CoV-2 感染之间的相关性。